

1449B/PTO
Rev. 10/95


U.S. Department of Commerce
Patent and Trademark Office

LIST OF PRIOR ART CITED BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/553,291
Filing Date	October 14, 2005
First Named Inventor	Mary J. EATON
Group Art Unit	1647
Examiner Name	GAMETT, Daniel C.
Attorney Docket Number	US 1442/05 (VA)



Sheet

1

of

4

Attorney Docket Number

US 1442/05 (VA)

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3) ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1 ⁶ if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (6-95)
Approved for use through 07/31/96, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO
Rev. 10/95

U.S. Department of Commerce
Patent and Trademark Office

Complete if Known

LIST OF PRIOR ART CITED BY APPLICANT

(use as many sheets as necessary)

Application Number **10/553,291**
Filing Date **October 14, 2007**
First Named Inventor **Mary J. EATON**
Group Art Unit **1647**
Examiner Name **GAMETT, Daniel C**
Attorney Docket Number **US 1442/05 (VA)**

JUN 09 2008

Sheet

2

of

4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T ²
		International Search Report and Written Opinion dated February 19, 2008, in International Application No. PCT/US05/38233 (6 pp.).	
		Abou-Donia, M.M., Wilson, S.P., Zimmerman, T.P., Nichol, C.A., Viveros, O.H. Regulation of guanosine triphosphate cyclohydrolase and tetrahydrobiopterin levels and the role of the cofactor in tyrosine hydroxylation in primary cultures of adrenomedullary chromaffin cells. J Neurochem, 46, 1190-1199 (1986).	
		Aunis, D., Hesketh, J., Devilliers, G. Immunohistochemical and immunocytochemical localization of myosin, chromogranin A and dopamine-β-hydroxylase in nerve cells in culture and adrenal glands. J Neurocytol, 9, 255-274 (1980).	
		Bachoud-Levi, A.C., Remy, P., Nguyen, J.P., Brugieres, P., Lefaucheur, J.P., Bourdet, C., Baudic, S., Gaura, V., Maison, P., Peschanski, M. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet, 356, 1975-1979 (2000).	
		Cahill, A.L., Eertmoed, L., Mangoura, D., Perlman, R. Differential regulation of phenylethanolamine-N-methyltransferase expression in two distinct subpopulations of bovine chromaffin cells. J. Neurochem., 67, 1217-1224 (1996).	
		Cairns L, Crotta S, Minuzzo M, Ricciardi-Castagnoli P, Pozzi L, Ottolenghi S: immortalization of neuro-endocrine cells from adrenal tumors arising in SV40 T-transgenic mice. Oncogene 14:3093-3098 (1997).	
		Czech KA, Sagen J: Update on cellular transplantation into the CNS as a novel therapy for chronic pain. Prog.Neurobiol. 46:507-529 (1995).	
		Duplan H, Bes JC, Tafani M, Sallerin B, Sagen J, Ohayon E, Lazorthes Y, Tkaczuk J: Adrenal medullary explants as an efficient tool for pain control: adhesive biomolecular components are involved in graft function ex vivo. Exp Neurol, 163:331-347(2000).	
		Eaton, M.J., Blits, B., Ruitenber, M.J., Verhaagen, J., Oudega, M. Amelioration of chronic neuropathic pain by adeno-associated viral (AAV) vector-mediated overexpression of BDNF in the rat spinal cord. Gene Ther, 9, 1387-1395 (2002a).	
		Eaton MJ: Emerging cell and molecular strategies for the study and treatment of painful peripheral neuropathies. J Peripher Nerv Sys 5:59-74 (2000).	

Examiner
Signature

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08B (6-95)
Approved for use through 07/31/96, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO
Rev. 10/95


U.S. Department of Commerce
Patent and Trademark Office

LIST OF PRIOR ART CITED BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/553,291
Filing Date	October 14, 2005
First Named Inventor	Mary J. EATON
Group Art Unit	1647
Examiner Name	GAMETT, Daniel C
Attorney Docket Number	US 1442/05 (VA)



Sheet

3

of

4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T ²
		Eaton, M.J., Gudehithlu, K.P., Quach, T., Silvia, C.P., Hadjiconstantinou, M., Neff, N.H. Distribution of aromatic L-amino acid decarboxylase mRNA in mouse brain by in situ hybridization histology. J. Comp. Neurol., 337, 640-654 (1993).	
		Eaton, M.J., Herman, J.P., Jullien, N., Lopez, T., Martinez, M., Huang, J. Immortalized chromaffin cells disimmortalized with Cre/lox site-directed recombination for use in cell therapy for pain. Exp Neurol, 175, 49-60 (2002b).	
		Giger, R.J., Wolfer, D.P., De Wit, G.M., Verhaagen, J. Anatomy of rat semaphorin III/collapsin-1 mRNA expression and relationship to developing nerve tracts during neuroembryogenesis. J Comp Nerol, 375, 378-392 (1996).	
		Lazorthes Y, Sagen J, Sallerin B, Tkaczuk J, Duplan H, Sol JC, Tafani M, Bes JC: Human chromaffin cell graft into the CSF for cancer pain management: a prospective phase II clinical study. Pain 87:19-32 (2000).	
		Muench, M.O., Ratcliffe, J.V., Nakanishi, M., Ishimoto, H., Jaffe, R.B. Isolation of definitive zone and chromaffin cells based upon expression of CD56 (neural cell adhesion molecule) in the human fetal adrenal gland. J Clin Endocrinol Metab, 88, 3921-3930 (2003).	
		Paillard F: Reversible cell immortalization with the cre-lox system. Hum.Gene Ther. 10:1597-1598 (1999).	
		Pal, R., Eaton, M.J., Islam, S., Hake-Frendscho, M., Kumar, K.N., Michaelis, E.K. Immunocytochemical and in situ hybridization studies of the expression and distribution of three subunits of a complex with N-methyl-D-aspartate receptor-like properties. Neurosci., 94, 1291-1311 (1999).	
		Pasterkamp, R.J., Giger, R.J., Ruitenber, M.J., Holtmaat, A., De Wit, J., de Winter, F., Verhaagen, J. Expression of the gene encoding the chemorepellent semaphorin III is induced in the fibroblast component of neural scar tissue formed following injuries of adult but not neonatal CNS. Mol Cell Neurosci, 13, 143-166 (1999).	
		Pear, W.S. III Transduction of genes using retrovirus vectors. In: Ausabel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seigman, J.G., Smith, J.A. & Struhl, K. (eds). Current protocols in molecular biology. John Wiley and Sons, New York (1995).	
		Pear, W.S., Nolan, G.P., Scott, M.L., Baltimore, D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Nat. Acad. Sci., U. S. A., 90, 8392-8396 (1993).	

Examiner
Signature

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (6-95)
 Approved for use through 07/31/96, OMB 0651-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO
 Rev. 10/95

U.S. Department of Commerce
 Patent and Trademark Office

LIST OF PRIOR ART CITED BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number **10/553,291**
 Filing Date **October 14, 2005**
 First Named Inventor **Mary J. EATON**
 Group Art Unit **1647**
 Examiner Name **GAMETT, Daniel C**
 Attorney Docket Number **US 1442/05 (VA)**

JUN 09 2008

Sheet

4

of

4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T ²
		Unsicker, K. & Muller, T.H. Purification of bovine adrenal chromaffin cells by differential plating. J. Neurosci. Meth., 4, 227-241 (1981).	
		Wang H, Sagen J: Attenuation of pain-related hyperventilation in adjuvant arthritic rats with adrenal medullary transplants in the spinal subarachnoid space. Pain 63:313-3201 (1995).	
		Duplan et al, Generation of conditionally immortalized cell lines genetically modified to over-express opioid peptides for chronic pain control, (Abstract) Exp Neurol, 175 (2): 433 (2002).	
		Wang X-T, Eaton MJ, Sagen J. Generation of conditionally immortalized serotonergic pineal cells for transplantation in chronic pain. Soc Neurosci, Abstract 23: 1455 (1997).	
		Kim P, Seasholtz AF, Sagen J. Generation of opioid-producing PC12 cells for transplantation in chronic pain. Amer Soc Neural Transpl, Abstract 3:34 (1996).	
		Kim PH, Wang X-T, Seasholtz A, Sagen J, Unnerstall JR. A met-enkephalin producing PC12 cell line as an alternative donor source for neural transplants in the reduction of chronic pain. Soc Neurosci, Abstract 22: 1021 (1996).	
		Eaton MJ, Frydel B, Lopez T, Nie XT, Huang J, McKillop J, Sagen J. Generation and initial characterization of conditionally immortalized chromaffin cells. J Cell Biochem., 79(1):38-57 (2000).	

Examiner
 Signature

Date
 Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.